Olfactory deficits are early features of preclinical Alzheimer’s disease (AD). Whether olfaction is associated with PET biomarkers among community-dwelling older adults is less clear.
Objective:
Investigate cross-sectional and longitudinal associations of olfaction with mild cognitive impairment (MCI) and amyloid-β (Aβ) and tau deposition.
Methods:
We analyzed 364 initially cognitively normal participants (58% women, 24% black) who had baseline olfaction data and subsequent cognitive assessments during an average 2.4-year. A subset of 129 had PET-PiB (Aβ) (n = 72 repeated) and 105 had 18F-flortaucipir (FTP)-PET (tau) (n = 44 repeated). Olfaction was measured using a 16-item Sniffin’ Sticks Odor Identification Test. The association of olfaction with incident MCI was examined using Cox regression. Associations with PiB-distribution volume ratio (DVR) and FTP-standardized uptake value ratio (SUVR) were examined using partial correlation. We tested whether PiB+/–status modified these associations. Analyses were adjusted for demographics and olfactory test version.
Results:
17 (5%) participants developed MCI. Each unit lower odor identification score was associated with 22% higher risk of developing MCI (p = 0.04). In the PET subset, lower scores were associated with higher mean cortical DVR and DVR in orbitofrontal cortex (OFC), precuneus, and middle temporal gyrus (p≤0.04). The “olfaction*PiB+/–” interaction in OFC DVR was significant (p = 0.03), indicating the association was limited to PiB positive individuals. Greater decline in odor identification score was associated with greater increase in anterior OFC DVR and entorhinal tau SUVR (p≤0.03).
Conclusion:
Among community-dwelling older adults, poorer olfaction predicts incident MCI and is associated with overall and regional Aβ. Greater olfaction decline is associated with faster Aβ and tau accumulation in olfaction-related regions. Whether olfaction predicts AD-related neurodegenerative changes warrants further investigations.
DotyRL, KamathV (2014) The influences of age on olfaction: A review. Front Psychol5, 20.
2.
DongJ, PintoJM, GuoX, AlonsoA, TranahG, CauleyJA, GarciaM, SatterfieldS, HuangX, HarrisT, MosleyTHJr., ChenH (2017) The prevalence of anosmia and associated factors among U.S. Black and white older adults. J Gerontol A Biol Sci Med Sci72, 1080–1086.
ParvandM, RankinCH (2020) Is there a shared etiology of olfactory impairments in normal aging and neurodegenerative disease?J Alzheimers Dis73, 1–21.
5.
TzengWY, FigarellaK, GaraschukO (2021) Olfactory impairment in men and mice related to aging and amyloid-induced pathology. Pflugers Arch473, 805–821.
6.
WilsonRS, SchneiderJA, ArnoldSE, TangY, BoylePA, BennettDA (2007) Olfactory identification and incidence of mild cognitive impairment in older age. Arch Gen Psychiatry64, 802–808.
7.
AdamsDR, KernDW, WroblewskiKE, McClintockMK, DaleW, PintoJM (2018) Olfactory dysfunction predicts subsequent dementia in older U.S. adults. J Am Geriatr Soc66, 140–144.
8.
YaffeK, FreimerD, ChenH, AsaoK, RossoA, RubinS, TranahG, CummingsS, SimonsickE (2017) Olfaction and risk of dementia in a biracial cohort of older adults. Neurology88, 456–462.
9.
RobertsRO, ChristiansonTJ, KremersWK, MielkeMM, MachuldaMM, VassilakiM, AlhuraniRE, GedaYE, KnopmanDS, PetersenRC (2016) Association between olfactory dysfunction and amnestic mild cognitive impairment and Alzheimer disease dementia. JAMA Neurol73, 93–101.
10.
DevanandDP, LeeS, ManlyJ, AndrewsH, SchupfN, DotyRL, SternY, ZahodneLB, LouisED, MayeuxR (2015) Olfactory deficits predict cognitive decline and Alzheimer dementia in an urban community. Neurology84, 182–189.
11.
FischerME, CruickshanksKJ, SchubertCR, PintoAA, CarlssonCM, KleinBE, KleinR, TweedTS (2016) Age-related sensory impairments and risk of cognitive impairment. J Am Geriatr Soc64, 1981–1987.
12.
Bahar-FuchsA, ChetelatG, VillemagneVL, MossS, PikeK, MastersCL, RoweC, SavageG (2010) Olfactory deficits and amyloid-beta burden in Alzheimer’s disease, mild cognitive impairment, and healthy aging: A PiB PET study. J Alzheimers Dis22, 1081–1087.
13.
TuL, LvX, FanZ, ZhangM, WangH, YuX (2020) Association of odor identification ability with amyloid-beta and tau burden: A systematic review and meta-analysis. Front Neurosci14, 586330.
14.
BaekMS, ChoH, LeeHS, LeeJH, RyuYH, LyooCH (2020) Effect of A/T/N imaging biomarkers on impaired odor identification in Alzheimer’s disease. Sci Rep10, 11556.
15.
KleinJ, YanX, JohnsonA, TomljanovicZ, ZouJ, PollyK, HonigLS, BrickmanAM, SternY, DevanandDP, LeeS, KreislWC (2021) Olfactory impairment is related to tau pathology and neuroinflammation in Alzheimer’s disease. J Alzheimers Dis80, 1051–1065.
16.
RisacherSL, TallmanEF, WestJD, YoderKK, HutchinsGD, FletcherJW, GaoS, KarekenDA, FarlowMR, ApostolovaLG, SaykinAJ (2017) Olfactory identification in subjective cognitive decline and mild cognitive impairment: Association with tau but not amyloid positron emission tomography. Alzheimers Dement (Amst)9, 57–66.
17.
GrowdonME, SchultzAP, DagleyAS, AmariglioRE, HeddenT, RentzDM, JohnsonKA, SperlingRA, AlbersMW, MarshallGA (2015) Odor identification and Alzheimer disease biomarkers in clinically normal elderly. Neurology84, 2153–2160.
18.
ReijsBLR, RamakersI, Elias-SonnenscheinL, TeunissenCE, Koel-SimmelinkM, TsolakiM, WahlundLO, WaldemarG, HausnerL, JohannsenP, VandersticheleH, VerheyF, DevanandDP, VisserPJ (2017) Relation of odor identification with Alzheimer’s disease markers in cerebrospinal fluid and cognition. J Alzheimers Dis60, 1025–1034.
19.
FerrucciL (2008) The Baltimore Longitudinal Study of Aging (BLSA): A 50-year-long journey and plans for the future. J Gerontol A Biol Sci Med Sci63, 1416–1419.
20.
DriscollI, DavatzikosC, AnY, WuX, ShenD, KrautM, ResnickSM (2009) Longitudinal pattern of regional brain volume change differentiates normal aging from MCI. Neurology72, 1906–1913.
21.
FuldPA (1978) Psychological testing in the differential diagnosis of the dementias. In Alzheimer’s Disease: Senile Dementia and Related Disorders, Katzman R, Terry RD, Bick KL, eds. Raven Press, New York, NY, pp. 185–193.
22.
MorrisJC (1993) The Clinical Dementia Rating (CDR): Current version and scoring rules. Neurology43, 2412–2414.
23.
PetersenRC, SmithGE, WaringSC, IvnikRJ, KokmenE, TangelosEG (1997) Aging, memory, and mild cognitive impairment. Int Psychogeriatr9(Suppl 1), 65–69.
24.
FolsteinMF, FolsteinSE, McHughPR (1975) “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res12, 189–198.
25.
ReitanRM (1992) Trail Making Test: Manual for administration and scoring, Reitan Neuropsychology Laboratory, Tucson, AZ.
NewcombeF (1969), Missile wounds of the brain: A study of psychological deficits, Oxford University Press, Oxford, UK.
28.
KaplanE, GoodglassH, WeintraubS (1983) The Boston Naming Test, Lea & Febiger, Philadelphia, PA.
29.
RouleauI, SalmonDP, ButtersN, KennedyC, McGuireK (1992) Quantitative and qualitative analyses of clock drawings in Alzheimer’s and Huntington’s disease. Brain Cogn18, 70–87.
30.
BuschkeH, KuslanskyG, KatzM, StewartWF, SliwinskiMJ, EckholdtHM, LiptonRB (1999) Screening for dementia with the memory impairment screen. Neurology52, 231–238.
31.
American Psychiatric Association (1987) Diagnostic and statistical manual of mental disorders. 3rd, American Psychiatric Association, Washington.
32.
McKhannG, DrachmanD, FolsteinM, KatzmanR, PriceD, StadlanEM (1984) Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology34, 939–944.
33.
HummelT, SekingerB, WolfSR, PauliE, KobalG (1997) ‘Sniffin’ sticks’: Olfactory performance assessed by the combined testing of odor identification, odor discrimination and olfactory threshold. Chem Senses22, 39–52.
34.
DoshiJ, ErusG, OuY, ResnickSM, GurRC, GurRE, SatterthwaiteTD, FurthS, DavatzikosC, Alzheimer’s Neuroimaging Initiative (2016) MUSE: MUlti-atlas region Segmentation utilizing Ensembles of registration algorithms and parameters, and locally optimal atlas selection. Neuroimage127, 186–195.
35.
BilgelM, Beason-HeldL, AnY, ZhouY, WongDF, ResnickSM (2020) Longitudinal evaluation of surrogates of regional cerebral blood flow computed from dynamic amyloid PET imaging. J Cereb Blood Flow Metab40, 288–297.
36.
BilgelM, AnY, ZhouY, WongDF, PrinceJL, FerrucciL, ResnickSM (2016) Individual estimates of age at detectable amyloid onset for risk factor assessment. Alzheimers Dement12, 373–379.
37.
KoychevI, VaciN, BilgelM, AnY, MunizGT, WongDF, GallacherJ, MogekharA, AlbertM, ResnickSM (2020) Prediction of rapid amyloid and phosphorylated-Tau accumulation in cognitively healthy individuals. Alzheimers Dement (Amst)12, e12019.
38.
ThomasBA, CuplovV, BousseA, MendesA, ThielemansK, HuttonBF, ErlandssonK (2016) PETPVC: A toolbox for performing partial volume correction techniques in positron emission tomography. Phys Med Biol61, 7975–7993.
39.
ZiontzJ, BilgelM, ShaferAT, MoghekarA, ElkinsW, HelphreyJ, GomezG, JuneD, McDonaldMA, DannalsRF, AzadBB, FerrucciL, WongDF, ResnickSM (2019) Tau pathology in cognitively normal older adults. Alzheimers Dement (Amst)11, 637–645.
40.
BeekmanAT, DeegDJ, Van LimbeekJ, BraamAW, De VriesMZ, Van TilburgW (1997) Criterion validity of the Center for Epidemiologic Studies Depression scale (CES-D): Results from a community-based sample of older subjects in The Netherlands. Psychol Med27, 231–235.
41.
KreislWC, JinP, LeeS, DayanER, VallabhajosulaS, PeltonG, LuchsingerJA, PradhabanG, DevanandDP (2018) Odor identification ability predicts PET amyloid status and memory decline in older adults. J Alzheimers Dis62, 1759–1766.
42.
VassilakiM, ChristiansonTJ, MielkeMM, GedaYE, KremersWK, MachuldaMM, KnopmanDS, PetersenRC, LoweVJ, JackCRJr., RobertsRO (2017) Neuroimaging biomarkers and impaired olfaction in cognitively normal individuals. Ann Neurol81, 871–882.
